Rifaximin - A non-resorbable antibiotic with many indications in gastroenterology;Rifaximin - ein nicht resorbierbares Antibiotikum mit vielfältigen Anwendungsmöglichkeiten in der Gastroenterologie

Zeitschrift fur Gastroenterologie

Volumn 49, Issue 2, 2011, Pages 211-214

  Rabenstein, T ^a   Fromm, M F ^b   Zolk, O ^b  

^a Diakonissen Stiftungs Krankenhaus Speyer   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

diverticular disease; infectious colitis; irritable bowel syndrome; lactose intolerance; pseudomembranous colitis; small bowel intestinal bacterial overgrowth

Indexed keywords

RIFAXIMIN;

ARTICLE; CLINICAL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; DIVERTICULOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERANCE; GASTROENTEROLOGY; GERMANY; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE INFECTION; PATHOGENESIS; PSEUDOMEMBRANOUS COLITIS; SMALL BOWEL INTESTINAL BACTERIAL OVERGROWTH; SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE; TRAVELLER DIARRHEA; TREATMENT INDICATION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; RIFAMYCINS;

EID: 79751523183     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245705     Document Type: Article

References (98)

1. Jiang Z D., Ke S, Palazzini E et al. In vitro activity and fecal concentration of rifaximin after oral administration. Anti (Pubitemid 30484455)
2. Descombe J J., Dubourg D, Picard M et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994 14 51-56 (Pubitemid 24289441)
3. Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 1999 44 1220-1221 (Pubitemid 29297232)
4. Rizzello F, Gionchetti P, Venturi A et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998 54 91-93 (Pubitemid 28189406)
5. Gomi H, Jiang Z D., Adachi J A. et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 2001 45 212-216 (Pubitemid 32039117)
6. Ruiz J, Mensa L, O'Callaghan C et al. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis 2007 59 473-475 (Pubitemid 350184234)
7. Steffen R, Sack D A., Riopel L et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 98 1073-1078 (Pubitemid 36733769)
8. Taylor D N., Bourgeois A L., Ericsson C D. et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006 74 1060-1066 (Pubitemid 351627416)
9. O'Connor J R., Galang M A., Sambol S P. et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008 52 2813-2817
10. De-Leo C, Eftimiadi C, Schito G C. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986 12 979-981 (Pubitemid 17040185)
11. Brigidi P, Swennen E, Rizzello F et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002 14 290-295 (Pubitemid 34734574)
12. Dupont H L., Jiang Z D. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 10 1009-1011
13. Fumi A L., Trexler K. Rifaximin treatment for symptoms of irritable bowel syndrome. Ann Pharmacother 2008 42 408-412 (Pubitemid 351429607)
14. Bertoli D, Borelli G. Teratogenic action of Rifaximin in the rat and rabbit and its effect on perinatal development in the rat. Boll Soc Ital Biol Sper 1984 60 1079-1085
15. Borelli G, Bertoli D. Acute, subacute, chronic toxicity and mutagenicity studies of rifaximin (L/ 105) in rats. Chemioterapia 1986 5 263-267 (Pubitemid 17230836)
16. Ma X, Shah Y M., Guo G L. et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007 322 391-398 (Pubitemid 46956365)
17. Trapnell C B., Connolly M, Pentikis H et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007 41 222-228 (Pubitemid 46340052)
18. Pentikis H S., Connolly M, Trapnell C B. et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007 27 1361-1369 (Pubitemid 47530442)
19. Dupont H L., Jiang Z D., Belkind-Gerson J et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007 5 451-456 (Pubitemid 46575371)
20. Dupont H L., Ericsson C D. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993 328 1821-1827
21. Ericsson C D., Dupont H L. Rifaximin in the treatment of infectious diarrhea. Chemotherapy 2005 51 /Suppl 1) 73-80 (Pubitemid 40663192)
22. Gillis J C., Brogden R N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995 49 467-484
23. Ruiz J, Mensa L, Pons M J. et al. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J Antimicrob Chemother 2008 61 1016-1019 (Pubitemid 351524441)
24. Vitali B, Turroni S, Serina S et al. Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin. Int J Antimicrob Agents 2008 31 555-560
25. Dupont H L., Ericsson C D., Mathewson J J. et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 1998 59 708-714 (Pubitemid 28510963)
26. Dupont H L., Jiang Z D., Ericsson C D. et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 33 1807-1815 (Pubitemid 33105118)
27. Dupont H L., Haake R, Taylor D N. et al. Rifaximin treatment of pathogen-negative travelers' diarrhea. J Travel Med 2007 14 16-19 (Pubitemid 46114982)
28. Dupont H L., Jiang Z D., Okhuysen P C. et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005 142 805-812 (Pubitemid 40664039)
29. Taylor D N., McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006 42 1283-1288
30. Taylor D N., McKenzie R, Durbin A et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008 52 1179-1181 (Pubitemid 351358412)
31. Jiang Z D., Dupont H L., La R M. et al. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol 2010 63 355-358
32. Dupont H L. Clinical practice. Bacterial diarrhea. N Engl J Med 2009 361 1560-1569
33. Dupont H L. Systematic review: the epidemiology and clinical features of travellers' diarrhoea. Aliment Pharmacol Ther 2009 30 187-196
34. Amenta M, le Nogare E R., Colomba C et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother 1999 11 391-395 (Pubitemid 29519214)
35. Schneider T, Eckmanns T, Ignatius R et al. Clostridium-difficile- assoziierte Diarrh : Ein zunehmendes klinisches Problem durch neue hochvirulente Erreger. Dtsch Arztebl 2007 104 1588-1594
36. Eichel-Streiber C, Braun V. Das difficile Clostridium. J Lab Med 2008 32 219-234
37. Gerding D N., Muto C A., Owens R C. et al. Treatment of Clostridium difficile infection. Clin Infect Dis 2008 46 (Suppl 1) S32-S42 (Pubitemid 351323663)
38. Kokkotou E, Moss A C., Michos A et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother 2008 52 1121-1126 (Pubitemid 351358396)
39. Surawicz C M. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy 2005 51 (Suppl 1) 81-89 (Pubitemid 40663193)
40. Garey K W., Salazar M, Shah D et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother 2008 42 827-835 (Pubitemid 351778089)
41. Boero M, Berti E, Morgando A et al. Treatment for colitis caused by Clostridium difficile: results of a randomized, open-label study of rifaximin vs. vancomycin. Microbiologia Medica 1990 5 74-77
42. Johnson S, Schriever C, Galang M et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007 44 846-848 (Pubitemid 46365312)
43. Garey K W., Jiang Z D., Bellard A et al. Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study. J Clin Gastroenterol 2009 43 91-93
44. Bascu P P., Diani A, Rayapudi K et al. Rifaximin salvage therapy for metranizole-resistant clostridium difficile infection - a prospective trial [Abstract]. Gastroenterology 2009 104 A1099
45. Curry S R., Marsh J W., Shutt K A. et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009 48 425-429
46. Wettstein M, Kircheis G, Häussinger D. Hepatische Enzephalopathie - Diagnostik. Dtsch Med Wochenschr 2003 128 2654-2657 (Pubitemid 38021445)
47. Als-Nielsen B, Gluud L L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004 328 1046
48. Bucci L, Palmieri G C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993 13 109-118 (Pubitemid 23187314)
49. De Marco F, Santamaria Amato P, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: A preliminary report. Curr Ther Res 1984 36 668-674 (Pubitemid 15128056)
50. DiPiazza S, Gabriella F M., Valenza L M. et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991 23 403-407
51. Fera G, Agostinacchio F, Nigro M et al. Rifaximin in the treatment of hepatic encophalopathy. Eur J Res 1993 4 109-118
52. Festi D, Mazzella G, Parini P et al. Treatment of hepatic encephalopathy with non-absorbable antibiotics. Ital J Gastroenterol 1992 24 14-16 (Pubitemid 23044053)
53. Loguercio C, Federico A, De G et al. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003 49 53-62 (Pubitemid 36505760)
54. Mas A, Rodes J, Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003 38 51-58 (Pubitemid 36078524)
55. Massa M D., Vallerino M D., Dodero M D. Treatment of hepatic encephalopathy with rifaximin: Double-blind, double-dummy study versus lactulose. Eur J Clin Res 1993 4 7-18
56. Miglio F, Valpiani D, Rossellini S R. et al. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997 13 593-601 (Pubitemid 27404093)
57. Parini P, Cipolla A, Ronchi M et al. Effect of rifaximin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992 52 34-39
58. Pedretti G, Calzetti C, Missale G et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991 23 175-178
59. Testa R, Eftimiadi C, Sukkar G S. et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985 11 387-392 (Pubitemid 15246073)
60. Williams R, James O F., Warnes T W. et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000 12 203-208 (Pubitemid 30166687)
61. Zeneroli M L., Avallone R, Corsi L et al. Management of hepatic encephalopathy: role of rifaximin. Chemotherapy 2005 51 (Suppl 1) 90-95 (Pubitemid 40663194)
62. Paik Y H., Lee K S., Han K H. et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005 46 399-407 (Pubitemid 40959882)
63. Bass N M., Mullen K D., Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010 362 1071-1081
64. Neff G W., Kemmer N, Zacharias V C. et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006 38 3552-3555 (Pubitemid 44908490)
65. Vlachogiannakos J, Saveriadis A S., Viazis N et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009 29 992-999
66. Attar A, Flourie B, Rambaud J C. et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999 117 794-797 (Pubitemid 29468220)
67. Peralta S, Cottone C, Doveri T et al. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol 2009 15 2628-2631
68. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005 51 (Suppl 1) 1-22 (Pubitemid 40663186)
69. Gasbarrini A, Lauritano E C., Gabrielli M et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig Dis 2007 25 237-240 (Pubitemid 350194175)
70. Lauritano E C., Gabrielli M, Lupascu A et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005 22 31-35 (Pubitemid 40943872)
71. Esposito I, De L A., Di G G. et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007 13 6016-6021 (Pubitemid 350238268)
72. Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006 52 89-95 (Pubitemid 43672299)
73. Majewski M, Sostarich S, Foran P et al. Is rifaximin effective treatment for small intestinal bacterial overgrowth? [ACG abstract 293]. Am J Gastroenterol 2006 101 Suppl S141
74. Scarpellini E, Gabrielli M, Lauritano C E. et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007 25 781-786 (Pubitemid 46434913)
75. Lauritano E C., Gabrielli M, Scarpellini E et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009 13 111-116
76. Di Stefano M, Malservisi S, Veneto G et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000 14 551-556 (Pubitemid 30240746)
77. Pimentel M, Park S, Mirocha J et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006 145 557-563 (Pubitemid 46780934)
78. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs 2009 18 349-358
79. Colecchia A, Sandri L, Capodicasa S et al. Diverticular disease of the colon: new perspectives in symptom development and treatment. World J Gastroenterol 2003 9 1385-1389 (Pubitemid 36992318)
80. Papi C, Koch M, Capurso L. Management of diverticular disease: is there room for rifaximin? Chemotherapy 2005 51 (Suppl 1) 110-114 (Pubitemid 40663197)
81. Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol 1992 24 452-456
82. Latella G, Pimpo M T., Sottili S et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003 18 55-62 (Pubitemid 36764140)
83. Papi C, Ciaco A, Koch M et al. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995 9 33-39
84. Colecchia A, Vestito A, Pasqui F et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007 13 264-269 (Pubitemid 46231330)
85. Di Mario F, Aragona G, Leandro G et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 2005 50 581-586 (Pubitemid 40543752)
86. Comparato G, Fanigliulo L, Aragona G et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis 2007 25 252-259 (Pubitemid 350194179)
87. Comparato G, Fanigliulo L, Cavallaro L G. et al. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007 52 2934-2941 (Pubitemid 47512549)
88. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 2002 34 510-515 (Pubitemid 34830693)
89. D'Inca R, Pomerri F, Vettorato M G. et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Aliment Pharmacol Ther 2007 25 771-779 (Pubitemid 46434919)
90. Tursi A, Brandimarte G, Giorgetti G M. et al. Assessment of small intestinal bacterial overgrowth in uncomplicated acute diverticulitis of the colon. World J Gastroenterol 2005 11 2773-2776 (Pubitemid 40704246)
91. Gionchetti P, Rizzello F, Morselli C et al. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 2005 51 (Suppl 1) 96-102 (Pubitemid 40663195)
92. Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology 2002 122 (Suppl 1) A434
93. Guslandi M, Giollo M, Testoni P A. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience. Curr Ther Res 2004 65 292-296 (Pubitemid 39360363)
94. Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999 13 713-718 (Pubitemid 29276839)
95. Isaacs K L., Sandler R S., Abreu M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007 13 1250-1255 (Pubitemid 47597772)
96. Shen B, Remzi F H., Lopez A R. et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008 8 26
97. Campieri M, Rizzello F, Venturi A et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomised controlled study vs mesalazine [Abstract]. Gastroenterology 2000 118 A781
98. Shafran I, Burgunder P. Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. Am J Gastroenterol 2008 103 2158-2160